Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.53 |
| ▸ | MMP9 | P14780 | 7/20 | 0.53 |
| ▸ | MMP3 | P08254 | 4/20 | 0.53 |
| ▸ | MMP1 | P03956 | 7/20 | 0.52 |
| ▸ | PTPRB | P23467 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798134 | 1.00 | MMP2 (0.53) | MMP2MMP9MMP3MMP1PTPRB | |
| SCHEMBL6801655 | 0.87 | TDP1 (0.57) | MMP2MMP9PTPRBLMNASMN1; SMN2 | |
| SCHEMBL6801645 | 0.87 | TDP1 (0.57) | MMP2MMP9PTPRBLMNASMN1; SMN2 | |
| SCHEMBL6804558 | 0.86 | HDAC1 (0.55) | MMP2MMP9MMP3MMP1PTPRB | |
| SCHEMBL6804556 | 0.86 | HDAC1 (0.55) | MMP2MMP9MMP3MMP1PTPRB | |
| SCHEMBL6912842 | 0.83 | POLB (0.56) | MMP2MMP9MMP3MMP1LMNA | |
| SCHEMBL6912827 | 0.83 | POLB (0.56) | MMP2MMP9MMP3MMP1LMNA | |
| SCHEMBL7381656 | 0.77 | MMP2 (0.75) | MMP2MMP9MMP3MMP1ALDH1A1 | |
| SCHEMBL7381660 | 0.77 | MMP2 (0.75) | MMP2MMP9MMP3MMP1ALDH1A1 | |
| SCHEMBL7971489 | 0.76 | MMP2 (0.59) | MMP2MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | claimed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | MMP2 630/4885MMP9 2969/4885MMP3 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.